Royalty PharmaRPRX
RPRX
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
466% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $3.2M
47% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 51
14% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 136
5% more funds holding
Funds holding: 389 [Q3] → 407 (+18) [Q4]
3.2% more ownership
Funds ownership: 68.8% [Q3] → 72.0% (+3.2%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 9 (+0) [Q4]
6% less capital invested
Capital invested by funds: $8.72B [Q3] → $8.16B (-$562M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for RPRX.
Financial journalist opinion
Neutral
MarketBeat
1 day ago
4 Healthcare Stocks With Massive Gains—and More to Come
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Neutral
GlobeNewsWire
3 days ago
Royalty Pharma Announces Upcoming Investor Day
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma's “Events” page at https://www.royaltypharma.com/investors/events/.
Positive
Seeking Alpha
1 month ago
17 Upcoming Dividend Increases, Including 3 Kings
This week's dividend increases feature three Dividend Kings: Archer-Daniels-Midland, Consolidated Edison, and Black Hills Corporation, with streaks of 50, 51, and 55 years, respectively. Consistently rising dividends indicate strong cash flow and financial stability, making such companies attractive long-term investments that often outperform benchmarks. My strategy focuses on stocks with consistent dividend growth and market outperformance, using data from U.S. Dividend Champions and NASDAQ.
Positive
Seeking Alpha
1 month ago
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend).
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus
Neutral
Seeking Alpha
1 month ago
Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citi Christopher Schott - JPMorgan Chase & Co Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Dina Ramadane - Bank of America Securities. Ashwani Verma - UBS Operator Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference.
Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma Reports Q4 and Full Year 2024 Results
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts.
Neutral
GlobeNewsWire
2 months ago
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive return by monetizing these future fixed payments at a low discount rate of 5.35% and will redeploy these proceeds into higher returning investment opportunities, including repurchasing its shares and acquiring attractive new royalties.
Charts implemented using Lightweight Charts™